Table 1

Indication for allo-SCT in CML

CML phaseClinical situationTKI and chemotherapy managementHLA typing and donor searchImmediate allo-SCT referral
CP First failure of imatinib, high risk Second-line TKI Yes No 
First failure of nilotinib or dasatinib Second-line TKI Yes Yes 
Failure to 2 TKIs Third-line TKI Yes Yes 
T315I mutation Ponatinib or omacetaxine Yes Yes 
AP TKI naïve TKI ± chemotherapy Yes Yes 
TKI naïve, without optimal response Second-line TKI ± chemotherapy Yes Yes 
TKI pretreated Second-line TKI ± chemotherapy Yes Yes 
BP TKI naïve or pretreated Induction chemotherapy, TKI Yes Yes 
CML phaseClinical situationTKI and chemotherapy managementHLA typing and donor searchImmediate allo-SCT referral
CP First failure of imatinib, high risk Second-line TKI Yes No 
First failure of nilotinib or dasatinib Second-line TKI Yes Yes 
Failure to 2 TKIs Third-line TKI Yes Yes 
T315I mutation Ponatinib or omacetaxine Yes Yes 
AP TKI naïve TKI ± chemotherapy Yes Yes 
TKI naïve, without optimal response Second-line TKI ± chemotherapy Yes Yes 
TKI pretreated Second-line TKI ± chemotherapy Yes Yes 
BP TKI naïve or pretreated Induction chemotherapy, TKI Yes Yes 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal